Vivus Inc said on Wednesday it will cease development of an experimental treatment for women with impaired sexual function due to low testosterone after finding that significant long-term safety requirements would be needed for the product to be approved.
Vivus is also developing Qnexa, a treatment for obesity, and avanafil for erectile dysfunction. Its shares fell 1.1 percent in premarket trading.
The company terminated its development agreement with FemPharm, which was originally signed in 2004, and will return rights to the product, Luramist.
“The decision to terminate the agreement was made in view of the significant long-term safety requirements for the approval of testosterone products in women,” said Peter Tam, president of Vivus.